Business Context and Reporting Period
This Form 8-K filing by Altimmune, Inc. covers the reporting period ending September 28, 2018. The document addresses a specific corporate event regarding the company's stock listing status on the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory compliance event rather than financial performance.
Material Changes
On September 28, 2018, Altimmune, Inc. received notice from the Nasdaq Listing Qualifications department that it had regained compliance with Nasdaq Listing Rule 5450(a)(1). This compliance was achieved because the closing bid price of the Company's common stock had been at $1.00 per share for more than ten consecutive business days.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No risks, contingencies, or unusual items are disclosed beyond the resolution of the prior listing deficiency.
Investor Verification Checklist
- Verify the current trading price of Altimmune, Inc. common stock to ensure continued compliance with Nasdaq listing requirements.
- Confirm the date the stock price first sustained the $1.00 threshold for ten consecutive business days.
- Review subsequent filings to ensure no new delisting notices have been issued.